Autoimmunity and Bone

Abstract:  Focal erosions of cartilage and bone, which occur in the joints of patients with autoimmune inflammatory arthritis (i.e., rheumatoid arthritis (RA) and psoriatic arthritis [PsA]), represent the most debilitating and irreversible components of the disease. Over the last decade, seminal breakthroughs in our understanding of the cells and signal transduction pathways central to this process have been elucidated. From this information an established paradigm has been developed to explain focal erosions in which osteoclasts responsible for erosions are derived from bone marrow‐derived myeloid precursors. Using the tumor necrosis factor (TNF) transgenic mouse model of erosive arthritis and anti‐TNF clinical trials with PsA patients, we have demonstrated that systemic TNF induces the migration of CD11b+ osteoclast precursors (OCP) from the bone marrow into peripheral blood. These OCP can then enter the joints in blood vessels, translocate across the receptor activator of NF‐κB ligand (RANKL) rich inflamed synovium, and differentiate into active osteoclasts. In direct contrast to this, systemic lupus erythematosus (SLE) patients appear to have an innate resistance to bone resorption. Our hypothesis to explain this phenomenon is that systemic interferon‐α (IFN‐α) diverts the bone marrow‐derived myeloid precursors away from the osteoclast lineage and stimulates their differentiation into dendritic cells (DC). In support of this model, several labs have used microarray analyses to define the IFN‐induced transcriptome in peripheral blood mononuclear cells (PBMC) from SLE patients. Here we propose the hypothesis that systemic TNF induces osteoclastic differentiation of PBMC in PsA patients that correlates with their erosive disease, and that the innate immune TNF/IFN axis in patients with autoimmune disease dictates their erosive phenotype. To demonstrate this, we injected wild‐type C57B/6 and TNF‐Tg mice with poly I:C, which is known to induce systemic IFN responses, and show its dominant effects on increasing the number of circulating CD11b+/CD11c+ precursor dendritic cells (pDC), concomitant with a dramatic reduction in CD11b+/CD11c− OCP. Thus, systemic factors produced by autoimmunity have a dramatic impact on active myelopoiesis and bone homeostasis.

[1]  V. Pascual,et al.  Autoimmunity through cytokine-induced dendritic cell activation. , 2004, Immunity.

[2]  E. Schwarz,et al.  RANK Signaling Is Not Required for TNFα‐Mediated Increase in CD11bhi Osteoclast Precursors but Is Essential for Mature Osteoclast Formation in TNFα‐Mediated Inflammatory Arthritis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  V. Pascual,et al.  The central role of dendritic cells and interferon-&agr; in SLE , 2003 .

[4]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[5]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[6]  D. Choubey,et al.  Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB Mice , 2003, The Journal of experimental medicine.

[7]  E. Schwarz,et al.  Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. , 2003, The Journal of clinical investigation.

[8]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Alexander Fraser,et al.  Angiopoietins, growth factors, and vascular morphology in early arthritis. , 2003, The Journal of rheumatology.

[10]  J. Meyers,et al.  Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. , 2002, The American journal of managed care.

[11]  E. Schwarz,et al.  Exposure to receptor-activator of NFκB ligand renders pre-osteoclasts resistant to IFN-γ by inducing terminal differentiation , 2002, Arthritis research & therapy.

[12]  C. Edwards Immune-mediated inflammatory disorders , 2002 .

[13]  D. Aaronson,et al.  A Road Map for Those Who Don't Know JAK-STAT , 2002, Science.

[14]  D. Goeddel,et al.  TNF-R1 Signaling: A Beautiful Pathway , 2002, Science.

[15]  Kozo Nakamura,et al.  RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β , 2002, Nature.

[16]  P. Mease,et al.  Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors , 2002, Annals of the rheumatic diseases.

[17]  W. Arend,et al.  The innate immune system in rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[18]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[19]  T. Vyse,et al.  Enhanced Susceptibility to Lupus Contributed from the Nonautoimmune C57BL/10, But Not C57BL/6, Genome1 , 2000, The Journal of Immunology.

[20]  C. Drake,et al.  Contributions of Ea(z) and Eb(z) MHC genes to lupus susceptibility in New Zealand mice. , 1998, Journal of immunology.

[21]  C. Drake,et al.  Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. , 1997, Journal of immunology.

[22]  C. Drake,et al.  Effect of genetic background on the contribution of New Zealand black loci to autoimmune lupus nephritis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  V T Farewell,et al.  Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. , 1995, The Journal of rheumatology.

[24]  C. Drake,et al.  Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner. , 1995, Journal of immunology.

[25]  L. Espinoza,et al.  Coexistence of human immunodeficiency virus infection and systemic lupus erythematosus. , 1995, The Journal of rheumatology.

[26]  S. Sarna,et al.  Correlations between clinical facets of outcome in rheumatoid arthritis. , 1993, Clinical and experimental rheumatology.

[27]  R. Luukkainen,et al.  How often is seropositive rheumatoid arthritis an erosive disease? A 17-year followup study. , 1993, The Journal of rheumatology.

[28]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[29]  E. Atra,et al.  A study of synovial membrane of patients with systemic lupus erythematosus (SLE). , 1991, Clinical and experimental rheumatology.

[30]  D. Resnick Bone and Joint Imaging , 1989 .

[31]  D. Woolley,et al.  Bidirectional erosion of cartilage in the rheumatoid knee joint. , 1985, Annals of the rheumatic diseases.

[32]  J. Esdaile,et al.  Deforming arthritis in systemic lupus erythematosus. , 1981, Annals of the rheumatic diseases.

[33]  D. Goldenberg,et al.  SYNOVIAL MEMBRANE HISTOPATHOLOGY IN THE DIFFERENTIAL DIAGNOSIS OF RHEUMATOID ARTHRITIS, GOUT, PSEUDOGOUT, SYSTEMIC LUPUS ERYTHEMATOSUS, INFECTIOUS ARTHRITIS AND DEGENERATIVE JOINT DISEASE , 1978, Medicine.

[34]  J. Edmonds,et al.  Systemic lupus erythematosus. A prospective analysis. , 1978, Annals of the rheumatic diseases.

[35]  H. Schumacher,et al.  Articular manifestations of systemic lupus erythematosus. , 1971, Annals of internal medicine.

[36]  Kaposi Neue Beiträge zurKenntniss des Lupus erythematosus , 1872, Archiv für Dermatologie und Syphilis.

[37]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases BioMed Central Review , 2006 .

[38]  E. Schwarz,et al.  Systemic tumor necrosis factor α mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor α–transgenic mice , 2004 .

[39]  E. Schwarz,et al.  Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. , 2004, Arthritis and rheumatism.

[40]  J. Bonnefoy,et al.  Interferon-γ switches monocyte differentiation from dendritic cells to macrophages , 2003 .

[41]  V. Pascual,et al.  The central role of dendritic cells and interferon-alpha in SLE. , 2003, Current opinion in rheumatology.

[42]  J. Bonnefoy,et al.  Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. , 2003, Blood.

[43]  M. Feldmann,et al.  Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. , 2003, Nature medicine.

[44]  P. Schur The clinical management of systemic lupus erythematosus , 1996 .

[45]  W. Eyler,et al.  PSORIATIC ARTHRITIS. , 1965, Henry Ford Hospital medical bulletin.